Literature DB >> 21515029

Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance.

Yuji Shigematsu1, Mareomi Hamada, Takayuki Nagai, Kazuhisa Nishimura, Katsuji Inoue, Jun Suzuki, Akiyoshi Ogimoto, Jitsuo Higaki.   

Abstract

BACKGROUND: We undertook a cross-sectional study to test the hypothesis that patients with hypertrophic cardiomyopathy (HCM) who have impaired left ventricular (LV) diastolic function are insulin resistant. We also evaluated the relation between the development of atrial fibrillation (AF) and insulin resistance (IR) in patients with HCM. METHODS AND
RESULTS: Eighty-eight patients with HCM (71 men, 17 women) were enrolled in the study. IR was estimated using the homeostasis model assessment (HOMA) index. Echocardiographically determined left atrial (LA) dimension was measured as a marker of LA size. The ratio of trasmitral early LV filling velocity to early diastolic mitral annulus velocity (E/e') was also measured as a marker of LV diastolic function. Twenty-seven patients (31%) had IR. Multivariate logistic regression analyses showed that independent determinants of AF were increased LA size [odds ratio (OR) 3.5, 95% confidence interval (CI) 1.2-9.8] and impaired LV diastolic function [OR 4.6, 95% CI 1.6-12.8]. The strongest determinant of LA size was the HOMA index (p = 0.0005). Similarly, the HOMA index (p = 0.0019) was an independent determinant of LV diastolic function.
CONCLUSION: IR is highly prevalent among non-diabetic patients with HCM. A possible mechanism by which IR affects the development of AF is mediated through its association with increased LA size or impaired LV diastolic function. IR may be an important underlying mechanism for the genesis of AF in HCM.
Copyright © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515029     DOI: 10.1016/j.jjcc.2011.03.001

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  7 in total

1.  Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.

Authors:  C Fielder Camm; A John Camm
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

2.  Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale.

Authors:  Tyler W Barrett; Alan B Storrow; Cathy A Jenkins; Frank E Harrell; Karen F Miller; Kelly M Moser; Stephan Russ; Dan M Roden; Dawood Darbar
Journal:  J Cardiol       Date:  2011-08-04       Impact factor: 3.159

3.  Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK.

Authors:  Hui Li; Xi Wang; Yiqing Mao; Ruobi Hu; Wei Xu; Zhen Lei; Na Zhou; Ling Jin; Tingting Guo; Zhixin Li; David M Irwin; Gang Niu; Huanran Tan
Journal:  Cardiovasc Diabetol       Date:  2014-01-22       Impact factor: 9.951

4.  Symptom burden, Metabolic profile, Ultrasound findings, Rhythm, neurohormonal activation, haemodynamics and health-related quality of life in patients with atrial Fibrillation (SMURF): a protocol for an observational study with a randomised interventional component.

Authors:  Emmanouil Charitakis; Ulla Walfridsson; Fredrik Nyström; Eva Nylander; Anna Strömberg; Urban Alehagen; Håkan Walfridsson
Journal:  BMJ Open       Date:  2015-12-21       Impact factor: 2.692

5.  Correlation between CH2DS2-VASc Score and Serum Leptin Levels in Cardioembolic Stroke Patients: The Impact of Metabolic Syndrome.

Authors:  Anna Szczepańska-Szerej; Jacek Kurzepa; Aneta Grabarska; Joanna Bielewicz; Ewa Wlizło-Dyś; Konrad Rejdak
Journal:  Int J Endocrinol       Date:  2017-10-31       Impact factor: 3.257

6.  Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.

Authors:  Ze-Min Yang; Long-Hui Chen; Min Hong; Ying-Yu Chen; Xiao-Rong Yang; Si-Meng Tang; Qian-Fa Yuan; Wei-Wen Chen
Journal:  Mol Med Rep       Date:  2017-02-22       Impact factor: 2.952

7.  Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies.

Authors:  Shang-Hung Chang; Lung-Sheng Wu; Meng-Jiun Chiou; Jia-Rou Liu; Kuang-Hui Yu; Chang-Fu Kuo; Ming-Shien Wen; Wei-Jan Chen; Yung-Hsin Yeh; Lai-Chu See
Journal:  Cardiovasc Diabetol       Date:  2014-08-10       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.